Sugi Predict

Sugi Predict / Compounds / SCHEMBL735068

SCHEMBL735068

SCHEMBL735068

O=c1c2ccccc2nc(C(S)c2ncnc3[nH]cnc23)n1N1CCOCC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 5/20 0.38
▸ ELANE P08246 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ HTT P42858 2/20 0.35
▸ SMN1; SMN2 Q16637 4/20 0.34
▸ ALDH1A1 P00352 3/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ NPY1R P25929 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ STAT1 P42224 1/20 0.34
▸ PIK3R2 O00459 1/20 0.34
▸ HIF1A Q16665 1/20 0.33
▸ PIK3CB P42338 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL734421 0.89 PIK3CD (0.40) PIK3CDALDH1A1KDM4EPIK3R2HIF1A
SCHEMBL734394 0.81 PIK3CD (0.51) PIK3CDALDH1A1LMNANPY1RPIK3CB
SCHEMBL734969 0.77 RAB9A (0.47) PIK3CDGAAHTTSMN1; SMN2ALDH1A1
SCHEMBL735178 0.77 PIK3CD (0.45) PIK3CDGAASMN1; SMN2ALDH1A1RAB9A
SCHEMBL735037 0.77 PIK3CG (0.47) PIK3CDSMN1; SMN2ALDH1A1KDM4ELMNA
SCHEMBL735069 0.76 PIK3CG (0.49) PIK3CDGAASMN1; SMN2ALDH1A1NPC1
SCHEMBL735090 0.75 ALDH1A1 (0.44) PIK3CDGAASMN1; SMN2ALDH1A1TSHR
SCHEMBL733470 0.74 PIK3CD (0.46) PIK3CDSMN1; SMN2ALDH1A1PIK3CB
SCHEMBL735268 0.74 L3MBTL1 (0.47) PIK3CDALDH1A1RAB9ATSHRMEN1
SCHEMBL734721 0.73 SMN1; SMN2 (0.51) PIK3CDGAASMN1; SMN2ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1278748-B1 INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA ICOS CORP (US) 2011-03-23 — — EP claimed
JP-4642309-B2 — — 2011-03-02 — — JP claimed
US-6800620-B2 CONTACTING LEUKOCYTES, OSTEOCLASTS WITH AN ENZYME INHIBITORS, A 9H-PURIN-3H-QUINAZOLIN-4-ONE DERIVATIVES, TREATING BONE-RESORPTION DISORDER, ANTIPROLIFERATIVE AGENTS TREATING LEUKEMIA CELLS ICOS 2004-10-05 — — US claimed
JP-2003531209-A — — 2003-10-21 — — JP claimed
US-20030195211-A1 Inhibitors of human phosphatidylinositol 3-kinase delta ICOS CORPORATION 2003-10-16 — — US claimed
EP-1278748-A2 INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA ICOS CORPORATION (US) 2003-01-29 — — EP claimed
WO-2001081346-A2 INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA ICOS CORPORATION (US) 2001-11-01 — — WO claimed
US-10695349-B2 Inhibitors of human phosphatidylinositol 3-kinase delta ICOS CORPORATION (US) 2020-06-30 — — US disclosed
US-20200061062-A1 INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA ICOS CORPORATION 2020-02-27 — — US disclosed
US-10398695-B2 Inhibitors of human phosphatidylinositol 3-kinase delta ICOS CORPORATION (US) 2019-09-03 — — US disclosed
US-20180360832-A1 INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA ICOS CORPORATION 2018-12-20 — — US disclosed
US-10010550-B2 Inhibitors of human phosphatidylinositol 3-kinase delta ICOS CORPORATION (US) 2018-07-03 — — US disclosed
US-20170340633-A1 INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA ICOS CORPORATION 2017-11-30 — — US disclosed
US-6667300-B2 Purinyl substituted quinazoline-4-one derivatives ICOS CORPORATION 2003-12-23 — — US disclosed
US-20030195211-A1 Inhibitors of human phosphatidylinositol 3-kinase delta ICOS CORPORATION 2003-10-16 — — US disclosed
WO-2003035075-A1 INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA ICOS CORPORATION (US) 2003-05-01 — — WO disclosed
US-6518277-B1 Disrupting leukocyte function ICOS CORPORATION 2003-02-11 — — US disclosed
EP-1278748-A2 INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA ICOS CORPORATION (US) 2003-01-29 — — EP disclosed
US-20020161014-A1 Purinyl substituted quinazoline-4-one derivatives ICOS CORPORATION, A DELAWARE CORPORATION 2002-10-31 — — US disclosed
WO-2001081346-A2 INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA ICOS CORPORATION (US) 2001-11-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170340633-A1 INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA PIK3CD, PIK3CA, PIK3CG PIK3CD 1/4885ELANE 2390/4885GAA 944/4885
US-20180360832-A1 INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA PIK3CD, PIK3CA, PIK3CG PIK3CD 1/4885ELANE 2390/4885GAA 944/4885
US-20020161014-A1 Purinyl substituted quinazoline-4-one derivatives PIK3CD, PIK3CA, PIK3CG PIK3CD 1/4885ELANE 1196/4885GAA 1941/4885
US-20200061062-A1 INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA PIK3CD, PIK3CA, PIK3CG PIK3CD 1/4885ELANE 2390/4885GAA 944/4885
US-20030195211-A1 Inhibitors of human phosphatidylinositol 3-kinase delta PIK3CD, PIK3CA, PIK3CG PIK3CD 1/4885ELANE 1805/4885GAA 836/4885
US-10695349-B2 Inhibitors of human phosphatidylinositol 3-kinase delta PIK3CD, PIK3CA, PIK3CG PIK3CD 1/4885ELANE 2390/4885GAA 944/4885
US-10010550-B2 Inhibitors of human phosphatidylinositol 3-kinase delta PIK3CD, PIK3CA, PIK3CG PIK3CD 1/4885ELANE 2390/4885GAA 944/4885
US-10398695-B2 Inhibitors of human phosphatidylinositol 3-kinase delta PIK3CD, PIK3CA, PIK3CG PIK3CD 1/4885ELANE 2390/4885GAA 944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.